B
Benoist Chibaudel
Researcher at British Hospital
Publications - 158
Citations - 5333
Benoist Chibaudel is an academic researcher from British Hospital. The author has contributed to research in topics: Colorectal cancer & Oxaliplatin. The author has an hindex of 32, co-authored 141 publications receiving 4272 citations. Previous affiliations of Benoist Chibaudel include University of Paris & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib the LAP07 randomized clinical trial
Pascal Hammel,Florence Huguet,Jean-Luc Van Laethem,David Goldstein,Bengt Glimelius,Pascal Artru,Ivan Borbath,Olivier Bouché,Jenny Shannon,Jenny Shannon,Thierry André,Laurent Mineur,Benoist Chibaudel,Franck Bonnetain,Christophe Louvet +14 more
TL;DR: In this open-label, randomized trial involving patients with locally advanced pancreatic cancer with disease controlled after 4 months of induction chemotherapy, there was no significant difference in overall survival with chemoradiotherapy compared with chemotherapy alone and there wasno significant difference with gem citabine compared with gemcitabine plus erlotinib used as maintenance therapy.
Journal ArticleDOI
Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study
Thierry André,Armand de Gramont,Dewi Vernerey,Benoist Chibaudel,Franck Bonnetain,Annemilaï Tijeras-Raballand,Aurelie Scriva,Tamas Hickish,Josep Tabernero,Jean-Luc Van Laethem,Maria Banzi,E. Maartense,Einat Shacham Shmueli,Göran Carlsson,Werner Scheithauer,Demetris Papamichael,Marcus Möehler,Stefania Landolfi,Pieter Demetter,Soudhir Colote,Christophe Tournigand,Christophe Louvet,Alex Duval,Jean François Fléjou,Aimery de Gramont +24 more
TL;DR: The OS benefit of oxaliplatin-based adjuvant chemotherapy, increasing over time and with the disease severity, was confirmed at 10 years in patients with stage II to III colon cancer, and updated results support the use of FOLFOX in Patients with stage III disease, including those with dMMR or BRAF mutation.
Journal ArticleDOI
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database
Jan Franko,Qian Shi,Jeffrey P. Meyers,Tim Maughan,Richard Adams,Matthew T. Seymour,Leonard B. Saltz,Cornelis J. A. Punt,Miriam Koopman,Christophe Tournigand,Niall C. Tebbutt,Eduardo Díaz-Rubio,John Souglakos,Alfredo Falcone,Benoist Chibaudel,Volker Heinemann,Joseph Moen,Aimery de Gramont,Daniel J. Sargent,Axel Grothey +19 more
TL;DR: The effect of the number and location of metastases in patients receiving first-line systemic chemotherapy is investigated to assess the prognostic associations of peritoneal metastatic colorectal cancer with overall survival and progression-free survival.
Journal ArticleDOI
Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study
Benoist Chibaudel,F. Maindrault-Goebel,Gérard Lledo,Laurent Mineur,Thierry André,M. Bennamoun,May Mabro,Pascal Artru,Elisabeth Carola,M. Flesch,Olivier Dupuis,Philippe Colin,Annette K. Larsen,Pauline Afchain,Christophe Tournigand,Christophe Louvet,Aimery de Gramont +16 more
TL;DR: The planned complete discontinuation of chemotherapy had a negative impact on DDC and PFS compared with the maintenance therapy strategy, suggesting that chemotherapy discontinuation cannot be decided before therapy is initiated in patients with advanced colorectal cancer.
Journal ArticleDOI
Adjuvant Therapy With Fluorouracil and Oxaliplatin in Stage II and Elderly Patients (between ages 70 and 75 years) With Colon Cancer: Subgroup Analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer Trial
Christophe Tournigand,Thierry André,Franck Bonnetain,Benoist Chibaudel,Gérard Lledo,Tamas Hickish,Josep Tabernero,Corrado Boni,Jean-Baptiste Bachet,Luis Augusto Teixeira,Aimery de Gramont +10 more
TL;DR: In this article, the authors performed subgroup analyses of stage II and elderly patients randomly assigned fluorouracil with leucovorin (FL) oxaliplatin (FOLFOX4) in the Multicenter International Study of Oxalplatin/ Fluorouracils/Leucovorsorin in the Adjuvant Treatment of Colon Cancer study.